© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Ixazomib Citrate stands as a significant molecule in cancer research and therapy, especially in treating multiple myeloma. Known by its molecular formula C20H23BCl2N2O9, this compound brings together boron, nitrogen, chlorine, and oxygen in an arrangement that impacts its stability and biological activity. The molecular weight clocks in near 517.12 g/mol, which gives some clues about how the compound moves and breaks down in both lab and medical environments. Researchers and pharmaceutical manufacturers rely on pristine Ixazomib Citrate as a raw material; a steady supply keeps developments in therapeutic options possible, reflecting its central role in modern medicine.
Ixazomib Citrate comes in several recognizable forms in laboratory settings. The pure powder appears white to off-white, reflecting a high degree of chemical purity. A close inspection shows a crystalline structure, which speaks to the regularity and strength of molecular bonds within the granules. Density holds steady at around 1.32 g/cm³, so measuring, mixing, and storing the substance doesn’t create handling problems for standard lab tools. Sometimes, Ixazomib Citrate gets delivered in flakes or pearls, but the solid powder is the most common. Each form brings its own handling quirks; powder flows smoothly for accurate weighing, while flakes resist clumping in humid rooms.
Safety takes the front seat with Ixazomib Citrate. The substance ranks as both hazardous and harmful, especially in pure form. Its low flash point and moderate reactivity mean labs need proper ventilation, gloves, goggles, and lab coats for every experiment or weighing session. Ixazomib Citrate reacts sharply with strong acids, strong bases, and certain oxidizing agents, so storage in a cool, dry, chemically compatible cabinet cuts down on accidents. Exposure through inhalation or skin contact brings risks of irritation and more serious toxicity, as documented in chemical safety protocols underlines its position as a controlled substance. Laboratories often store it in well-marked containers — a clear move aligned with best practices seen worldwide.
Taking a closer look inside the molecule, Ixazomib Citrate contains a boronic acid group, two chlorine atoms, and a citrate group. The citrate part increases solubility, making it easier for this molecule to dissolve in water or saline solution — a major advantage in drug formulation. This group also affects how the molecule interacts with human cells, and how it gets absorbed, distributed, and eliminated by the body. Scientists praise the clear-cut structure’s effect on pharmacokinetics, but it also means regulatory agencies ask for tight, methodical testing.
Ixazomib Citrate sits under the HS Code 2942.00, the international tariff code for organic compounds used in pharmaceutical research and manufacturing. Product specifications ask that every batch shows a purity above 98%, confirmed through high-performance liquid chromatography (HPLC) and nuclear magnetic resonance (NMR) tests. Water content levels stay under 1.5%, a threshold balancing safety and stability. Bulk shipments usually come in sealed glass or certified chemical-resistant plastic bottles, labeled with specification sheets and MSDS (Material Safety Data Sheet), following strict health and chemical import regulations from customs authorities.
For all its promise, Ixazomib Citrate requires careful logistics in storage and disposal. Laboratories need regular training sessions for anyone handling small or large quantities. Spill kits stocked with neutralizing agents and absorbent material stay close at hand, cutting the danger of contamination or injury. Digital inventory systems flag when stocks approach expiration, which keeps expired material out of active studies. To reduce harmful exposure, fume hoods run during weighing and testing. Safe disposal involves third-party hazardous waste firms, who incinerate or chemically treat residual powder following environmental protection laws.
My experience in medical research brings out the huge role Ixazomib Citrate plays in new medicine development. Every time a new cancer therapy shows promise in the clinic, there’s a complex trail of raw materials, safety reviews, chemical synthesis, and stability tests behind that single dose. With Ixazomib Citrate, tightening purity and improving safety standards mean patients face fewer risks if they get these therapies. Every lab tech, pharmacist, and researcher who works with it knows the stakes — the right handling not only protects those in the lab, but also delivers more reliable research results. With evolving regulations and growing demand for safe cancer drugs, better tracking, robust safety measures, and high transparency help keep Ixazomib Citrate a trusted part of medicine’s future toolkit.
